Form 4: Allogene Therapeutics CFO Reports Purchase of Shares Through Trust Account

Allogene Therapeutics CFO Geoffrey M. Parker reports the purchase of 190 shares of common stock through a trust account, with subsequent restrictions placed to prevent future occurrences.

Summary

• On January 30, 2024, Geoffrey M. Parker, the Chief Financial Officer of Allogene Therapeutics, Inc., acquired 190 shares of common stock at a price of $3.595 per share.
• The purchase was made through an account held by the Geoffrey M. Parker and Jill G. Parker Rev. Trust dated January 27, 2000.
• Mr. Parker was notified of the purchase by his broker on March 4, 2024.
• Mr. Parker does not have discretion over this account, which is designed to closely track the performance of the Russell 2000 and is frequently rebalanced by an algorithm.
• Following the reported transaction, Mr. Parker beneficially owns 819,590 shares of Allogene Therapeutics common stock.
• Restrictions have been placed on all such accounts held by the Trust to prevent future purchases of Allogene Therapeutics stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the purchase itself is not inherently negative, the circumstances surrounding it (lack of direct control, automated trading) introduce a slight element of concern regarding compliance and internal controls.

Positives

• Restrictions have been put in place to prevent similar purchases in the future, suggesting proactive management of potential conflicts of interest.

Negatives

• The purchase occurred without the CFO's direct control, raising questions about internal compliance procedures.

Risks

• The incident highlights potential risks related to automated investment strategies and the need for robust compliance oversight.
• Future similar incidents could raise concerns about insider trading or conflicts of interest, even if unintentional.

Industry Context

This type of disclosure is standard for corporate insiders and is required to maintain transparency in the market. It is common for executives to have personal investment accounts, but it is important to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• Similar disclosures are routinely filed by executives at comparable biotechnology companies such as Gilead Sciences, Amgen, and Biogen.
• These filings are a standard part of maintaining market transparency and ensuring compliance with SEC regulations.
• The circumstances surrounding this particular purchase, involving an automated trading algorithm, are less common but highlight the increasing complexity of personal investment management for corporate insiders.

Stakeholder Impact

• The incident could raise concerns among shareholders regarding the CFO's personal investment activities and potential conflicts of interest.
• Employees may be concerned about compliance procedures and the potential for insider trading violations.

Key Dates